NASDAQ:REGN

Regeneron Pharmaceuticals Stock News

etoro logo Buy REGN
*Your capital is at risk
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited production of Regeneron Pharmace
We have narrowed down our search to five large-cap stocks that have given double-digit returns in the past three months. These are: CLR, DAR, REGN, ORLY and MOS.
Shares of Regeneron Pharmaceuticals Inc. REGN, -0.08% were down 0.1% in premarket trading on Friday after the World Health Organization recommended its monoclonal antibody as a treatment for COVID-19.
The health agency also joined calls for Regeneron to boost access to its drug, ramp up production and lower its prices to ensure it is distributed fairly.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Regeneron (REGN).
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX
OneMain Holdings (OMF), KLA Corporation (KLAC), Bunge Limited (BG), CBRE Group, (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as markets await Fed tapering cl
With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's (
New Dupixent ® (dupilumab) data in patients as young as 6 years old with moderate -to-severe a topic dermatitis to be presented at WCPD and EADV
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.  According to data released at the European So

AbbVie's Pain Is Sanofi's and Regeneron's Gain

05:57am, Saturday, 18'th Sep 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE